Stem cell therapy for Parkinson’s disease requires demonstration of safety and efficacy of dopaminergic cells derived from a cell line, consideration of dose, and whether this is deliverable at scale. Park et al. demonstrate these requirements for a new hESC line and that their manufacturing methods allow for its scalability.

中文翻译：

---

扩大 GMP 级多巴胺能细胞治疗帕金森病的规模

帕金森病的干细胞疗法需要证明来自细胞系的多巴胺能细胞的安全性和有效性，考虑剂量以及是否可以大规模交付。帕克等人。展示了新 hESC 生产线的这些要求，以及其制造方法可实现其可扩展性。